Jefferies Financial Group initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research note issued to investors on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $31.00 target price on the stock.
Separately, Goldman Sachs Group started coverage on shares of Allogene Therapeutics in a research report on Monday. They set a buy rating and a $41.00 target price for the company.
Allogene Therapeutics stock opened at $32.68 on Monday. Allogene Therapeutics has a twelve month low of $21.67 and a twelve month high of $35.55.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.